SYSTEMS, DEVICES, AND METHODS FOR PASSIVE TRANSDERMAL DELIVERY OF ACTIVE AGENTS TO A BIOLOGICAL INTERFACE

• US 20080286349A1
• Filed: 05/16/2008
• Published: 11/20/2008
• Est. Priority Date: 05/18/2007
• Status: Abandoned Application

• Current Assignee: TTI Ellebeau, Inc. (Ease Asset Management Ltd.)
• Original Assignee: TTI Ellebeau, Inc. (Ease Asset Management Ltd.)
• Inventors: Kanamura, Kiyoshi, Ishida, Mayuko, Ishikawa, Chizuko, Nomoto, Youhei, Saito, Akiyoshi, Ishikawa, Izumi
• Application Number:
  US12/122,630
• Publication Number:
  US 20080286349A1
• Time in Patent Office: Days
• US Class Current: 424/449
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/196 the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• CPC Class Codes: A61K 31/473 ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids

Abstract

Systems, devices, and methods for transdermal delivery of one or more therapeutic active agents to a biological interface. A transdermal drug delivery system is provided for passive transdermal delivery of one or more ionizable active agents to a biological interface of a subject. A transdermal drug delivery system includes a backing substrate, and an active agent layer. The active layer includes a thickening agent, a plasticizer, and a therapeutically effective amount of an ionizable active agent.

Claims

1. A passive transdermal delivery device comprising:

a backing substrate; and

an active agent layer, wherein the active agent layer is substantially anhydrous and oil-free and includes a thickening agent and an ionizable active agent, and wherein the ionizable active agent is electrically neutral in the active agent layer and dissociates into an ionized active agent upon contacting an aqueous medium.

2. The passive transdermal delivery device of claim 1 wherein the ionizable active agent is a salt of an amine-containing active agent.

3. The passive transdermal delivery device of claim 2 further comprising a humectant.

4. The passive transdermal delivery device of claim 2 wherein the thickening agent is HPC, the ionizable active agent is Procaterol HCl and the humectant is urea.

5. The passive transdermal delivery device of claim 2 wherein the ionizable active agent is a β

-adrenergic agonist.

6. The passive transdermal delivery device of claim 3 wherein the β

-adrenergic agonist is Procaterol HCl.

7. The passive transdermal delivery device of claim 2 wherein the ionizable active agent is a “

caine”

class analgesic or anesthetic.

8. The passive transdermal delivery device of claim 7 wherein the ionizable active agent is Lidocaine HCl.

9. The passive transdermal delivery device of claim 1 wherein the ionizable active agent is a salt of a carboxylic acid-containing active agent.

10. The passive transdermal delivery device of claim 9 wherein the ionizable active agent is alkaline Diclofenac.

11. The passive transdermal delivery device of claim 1 wherein the ionizable active agent is L-ascorbic acid or a derivative thereof.

12. The passive transdermal delivery device of claim 11 wherein the ionizable active agent is ascorbic acid 2-glucoside.

13. The passive transdermal delivery device of claim 1 wherein the thickening agent is a cellulose derivative.

14. The passive transdermal delivery device of claim 13 wherein the thickening agent is hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxypropyl methylcellulose, or a combination thereof.

15. The passive transdermal delivery device of claim 14 further comprising one or more humectants selected from urea, glycerine, propylene glycol, glyceryl triacetate, and polyols.

16. The passive transdermal delivery device of claim 1 wherein at least 50% of an initial amount of the ionizable active agent is permeable through skin.

17. The passive transdermal delivery device of claim 16 wherein the ionizable active agent is Procaterol HCl.

18. The passive transdermal delivery device of claim 1 further comprising an ionizable additive.

19. The passive transdermal delivery device of claim 18 wherein the ionizable active agent is an alkaline Diclofenac and the ionizable additive is potassium chloride.

20. The passive transdermal delivery device of claim 1 further comprising a replenish layer including additional ionizable active agent and an ion exchange material.

21. A topical formulation comprising:

a thickening agent,

an ionized active agent; and

an aqueous medium, wherein the topical formulation is substantially oil-free.

22. The topical formulation of claim 21 wherein the thickening agent is a cellulose derivative.

23. The topical formulation of claim 21 wherein the ionized active agent is cationic Procaterol cation, anionic Diclofenac, cationic Lidocaine or anionic AA2G.

24. A method of treating a condition associated with an obstructive respiratory ailment in a subject comprising:

applying to the subject'"'"'s skin a passive transdermal delivery device comprising;

a backing substrate; and

an active agent layer, wherein the active agent layer is substantially anhydrous and oil-free and includes a thickening agent and an ionizable active agent, and wherein the ionizable active agent is electrically neutral in the active agent layer and dissociates into an ionized active agent upon contacting an aqueous medium; and

allowing the ionizable active agent to dissociate into the ionized active agent.

25. The method of claim 24 comprising contacting the ionizable active agent to sweat of the subject'"'"'s skin to produce the ionized active agent.

26. The method of claim 25 wherein the ionizable active agent is Procaterol HCl.

27. The method of claim 25 wherein the active agent layer further comprises a humectant.

28. The method of claim 24 wherein the active agent layer comprises HPC, Procaterol HCl and urea.

29. The method of claim 24 wherein at least 50% of the Procaterol HCl is delivered through the skin of the subject within a 24 hour period.